| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4272290 | The Journal of Sexual Medicine | 2010 | 11 Pages |
Abstract
Vardenafil was effective in men with dyslipidemia regardless of LDL-C levels, TC/HDL-C ratio, and/or presence of metabolic syndrome. Despite the known presence of ED and dyslipidemia, other cardiovascular risk factors were apparently not aggressively managed. Miner MM, Barnes A, and Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: A post hoc analysis of the vardenafil statin study.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Martin M. MD, Allison MS, Stephen Pharm.D.,